Evaluation of the Effectiveness of PermeaDerm® (PD) as Compared to Mepilex Ag®

Thermal Burn Clinical Trial

Official title:

An Adaptive, Randomized, Controlled Trial Evaluating the Effectiveness of PermeaDerm® (PD) as Compared to Mepilex Ag® Used as Standard of Care in the Treatment of Adult and Pediatric Partial Thickness Burns.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05084183
• Other study ID #: ST-2021-B001
• Status: Recruiting
• Phase: N/A
• Start date: February 2, 2022
• Est. completion date: November 2023

Study information

• Verified date: June 2022
• Source: Stedical Scientific, Inc.
• Contact: Miao Yu, Ph.D
• Phone: 1-858-753-9530
• Email: miao.yu[@]stedical.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A total of 68 adult and pediatric patients who suffer from at least one discrete partial thickness thermal burn wound (Grade II) will be recruited. Subjects will be randomized (1:1) to either PermeaDerm® or Mepilex Ag®. Evaluations will occur at 7, 14 and 21 days with long term follow-up at 6 and 12 months.

Description:

A total of 68 adult and pediatric patients who suffer from at least one discrete partial thickness thermal burn wound (Grade II) will be recruited from the clinical practices of the site Principal Investigators.

Participants and/or the Legally Authorized Representative (LAR) as appropriate will be fully informed regarding the conduct of the clinical trial including all potential risks and benefits.

All Participants must be consented, randomized (1:1) and treated within 72 hours of injury.

It is permissible for a Study Participant to be enrolled if they have more than one burn wound.

If more than one partial thickness burn is treated, the Investigator must indicate prior to randomization which wound is to be considered for primary analysis. This wound will be called the Primary Wound and is to be evaluated by a Blinded Assessor.

Additional partial thickness wounds must be treated with the same product to which the Study Participant was randomized and will be included in secondary analysis. These wounds are to be described as Secondary Wounds and are to be evaluated by the Unblinded Assessor.

Evaluations will occur at 7, 14 and 21 days with long term follow-up at 6 and 12 months.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 68
• Est. completion date: November 2023
• Est. primary completion date: November 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 75 Years

Eligibility

Inclusion Criteria:

Participants will be included if all the following criteria are met.

1. Able to give informed consent and undergo treatment < 72 hours of injury (consent may be given by LAR as necessary);

2. Any adult or pediatric patient < 75 years of age;

3. Target burn to be at least one discrete partial thickness (second degree) thermal burns <20% total body surface area (TBSA) on anybody surface except the face;

4. Characteristics of treated wound (s) must be superficial to deep partial thickness wounds such that application of both PermeaDerm and Mepilex Ag is medically appropriate;

5. Agrees to abstain from the use of any other wound covering device for the duration of the study unless determined by the individual site Principal Investigator to be medically necessary;

6. Demonstrates the ability and willingness to follow the requirements of the protocol.

Exclusion Criteria:

Participants will be excluded if s/he meet any of the following criteria.

1. Pregnant or breastfeeding;

2. Target burn = 20% TBSA;

3. Electrical burns, chemical burns, frostbite;

4. Treatment with silver sulfadiazine prior to presentation;

5. Has comorbidities and/or medications and/or health status that (at the discretion of the individual site Principal Investigator) could result in poor wound healing (some examples may include admission to intensive care unit, inhalation, or other significant burn associated conditions, uncontrolled and/or significant diabetes, peripheral vascular disease, active malignancy, autoimmune disease, smoking, drug abuse, renal failure, steroid usage.

Related Conditions & MeSH terms

• Thermal Burn

Intervention

Device:
• PermeaDerm®
Wound Management Device
• Mepilex Ag
Wound Dressing

Locations

Country	Name	City	State
United States	University of California, Davis	Sacramento	California

Sponsors (1)

Lead Sponsor	Collaborator
Stedical Scientific, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Reepithelialization	Time to 100 percent- primary wound	14 days
Primary	Alternate therapy	Time to conversion to alternate therapy- primary wound	14 days
Secondary	Re-epithelialization	Percent reepithelialization primary and secondary Wounds	14 days
Secondary	Alternate therapy	Time to conversion to alternate therapy- secondary wounds	up to 12 Months
Secondary	Adverse Events	Occurrence, duration, severity, seriousness, expectedness, and relationship of adverse events	21 days
Secondary	Severity of pain	Wong-Backer Faces pain rating scale and in adults as measured by the Numerical Rating Scale (0-10);	Up to 12 Months
Secondary	Scar characteristics	Patient and Observer Scar Assessment Scale (POSAS)	6 and 12 months
Secondary	Satisfaction with treatment	Brisbane Burn Scar Impact Profile (BBSIP)	6 and 12 months
Secondary	Dressing Changes Required	Number	Up to 21 Days